Cargando…

A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer

To explore the antitumor effect of hypoxia-inducible factor-1α short hairpin RNA (HIF-1α shRNA) delivered by ultrasound targeted microbubble destruction (UTMD) and transcatheter arterial embolization (TAE) on rats with hepatic cancer. After the models of transplantation hepatoma were established, Wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Yangying, Luo, Haibo, He, Zhizhong, Kuang, Yongpei, Chen, Peifen, Zhang, Xiuzhen, Chen, Junjun, Wen, Qirong, Xie, Yuhuan, Ding, Shangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399560/
https://www.ncbi.nlm.nih.gov/pubmed/30911540
http://dx.doi.org/10.1155/2019/1937460
_version_ 1783399784449572864
author Liao, Yangying
Luo, Haibo
He, Zhizhong
Kuang, Yongpei
Chen, Peifen
Zhang, Xiuzhen
Chen, Junjun
Wen, Qirong
Xie, Yuhuan
Ding, Shangwei
author_facet Liao, Yangying
Luo, Haibo
He, Zhizhong
Kuang, Yongpei
Chen, Peifen
Zhang, Xiuzhen
Chen, Junjun
Wen, Qirong
Xie, Yuhuan
Ding, Shangwei
author_sort Liao, Yangying
collection PubMed
description To explore the antitumor effect of hypoxia-inducible factor-1α short hairpin RNA (HIF-1α shRNA) delivered by ultrasound targeted microbubble destruction (UTMD) and transcatheter arterial embolization (TAE) on rats with hepatic cancer. After the models of transplantation hepatoma were established, Wistar rats were randomly divided into 4 groups: Control group, UTMD group, TAE group, and UTMD+TAE group. Contrast-enhanced ultrasound (CEUS) was used to monitor tumor size on day 14 after four different treatments. Western blotting and immunohistochemistry were applied to measure the protein level of HIF-1α and VEGF in the hepatic cancer tissue. In comparison with UTMD+TAE group (21.25±10.68 days), the mean survival time was noticeably shorter in the Control group and TAE group (13.02±4.30 days and 15.03±7.32 days) (p<0.05, respectively). There was no statistical difference between UTMD+TAE group and UTMD group of the mean survival time (p>0.05). In addition, our results proved that the tumor sizes in UTMD+TAE group were obviously smaller than those in other groups (p<0.05, respectively). By CEUS, we clearly found that the tumor size was the smallest on day 14 in the UTMD+TAE group. The western blotting and immunohistochemistry results proved that the protein levels of HIF-1α and VEGF in UTMD+TAE group were obviously lower than those in TAE group and Control group on days 7 and 14 (p<0.05, respectively). However, there was no statistical difference between UTMD+TAE group and UTMD group (p>0.05). In this study we tried to explore the antitumor effect through a combination of UTMD-mediated HIF-1α shRNA transfection and TAE on rats with hepatic cancer. Our results showed that UTMD-mediated HIF-1α shRNA transfection and TAE can obviously silence HIF-1α and VEGF expression, thereby successfully inhibiting the growth of the tumor.
format Online
Article
Text
id pubmed-6399560
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63995602019-03-25 A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer Liao, Yangying Luo, Haibo He, Zhizhong Kuang, Yongpei Chen, Peifen Zhang, Xiuzhen Chen, Junjun Wen, Qirong Xie, Yuhuan Ding, Shangwei Biomed Res Int Research Article To explore the antitumor effect of hypoxia-inducible factor-1α short hairpin RNA (HIF-1α shRNA) delivered by ultrasound targeted microbubble destruction (UTMD) and transcatheter arterial embolization (TAE) on rats with hepatic cancer. After the models of transplantation hepatoma were established, Wistar rats were randomly divided into 4 groups: Control group, UTMD group, TAE group, and UTMD+TAE group. Contrast-enhanced ultrasound (CEUS) was used to monitor tumor size on day 14 after four different treatments. Western blotting and immunohistochemistry were applied to measure the protein level of HIF-1α and VEGF in the hepatic cancer tissue. In comparison with UTMD+TAE group (21.25±10.68 days), the mean survival time was noticeably shorter in the Control group and TAE group (13.02±4.30 days and 15.03±7.32 days) (p<0.05, respectively). There was no statistical difference between UTMD+TAE group and UTMD group of the mean survival time (p>0.05). In addition, our results proved that the tumor sizes in UTMD+TAE group were obviously smaller than those in other groups (p<0.05, respectively). By CEUS, we clearly found that the tumor size was the smallest on day 14 in the UTMD+TAE group. The western blotting and immunohistochemistry results proved that the protein levels of HIF-1α and VEGF in UTMD+TAE group were obviously lower than those in TAE group and Control group on days 7 and 14 (p<0.05, respectively). However, there was no statistical difference between UTMD+TAE group and UTMD group (p>0.05). In this study we tried to explore the antitumor effect through a combination of UTMD-mediated HIF-1α shRNA transfection and TAE on rats with hepatic cancer. Our results showed that UTMD-mediated HIF-1α shRNA transfection and TAE can obviously silence HIF-1α and VEGF expression, thereby successfully inhibiting the growth of the tumor. Hindawi 2019-02-19 /pmc/articles/PMC6399560/ /pubmed/30911540 http://dx.doi.org/10.1155/2019/1937460 Text en Copyright © 2019 Yangying Liao et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liao, Yangying
Luo, Haibo
He, Zhizhong
Kuang, Yongpei
Chen, Peifen
Zhang, Xiuzhen
Chen, Junjun
Wen, Qirong
Xie, Yuhuan
Ding, Shangwei
A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer
title A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer
title_full A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer
title_fullStr A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer
title_full_unstemmed A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer
title_short A Combination of UTMD-Mediated HIF-1α shRNA Transfection and TAE in the Treatment of Hepatic Cancer
title_sort combination of utmd-mediated hif-1α shrna transfection and tae in the treatment of hepatic cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399560/
https://www.ncbi.nlm.nih.gov/pubmed/30911540
http://dx.doi.org/10.1155/2019/1937460
work_keys_str_mv AT liaoyangying acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT luohaibo acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT hezhizhong acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT kuangyongpei acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT chenpeifen acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT zhangxiuzhen acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT chenjunjun acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT wenqirong acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT xieyuhuan acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT dingshangwei acombinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT liaoyangying combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT luohaibo combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT hezhizhong combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT kuangyongpei combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT chenpeifen combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT zhangxiuzhen combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT chenjunjun combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT wenqirong combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT xieyuhuan combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer
AT dingshangwei combinationofutmdmediatedhif1ashrnatransfectionandtaeinthetreatmentofhepaticcancer